Mirja Harms

9PUBLICATIONS
42CO-AUTHORS
Cancer geneticsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityReaction engineering (excl. nuclear reactions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 20, 2025
GPR15LG binds CXCR4 and synergistically modulates CXCL12-induced cell signaling and migration.

Dan Pascal Jean Albers, Sofya Novikova, Julio Vieyto-Nuñez

|Mar 13, 2025
CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma.

Nupur Khunti, Manish Kumar, Moumita Datta

|Jan 09, 2025
Improving Affinity while Reducing Kidney Uptake of CXCR4-Targeting Radioligands Derived from the Endogenous Antagonist EPI-X4.

Raghuvir H Gaonkar, Thibaud Bailly, Jacopo Millul

|Sep 17, 2024
A naturally occurring 22-amino acid fragment of human hemoglobin A inhibits autophagy and HIV-1.

Dennis Freisem, Armando A Rodriguez-Alfonso, Jan Lawrenz

|Aug 10, 2024
An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR-ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia.

Johanna Pohl, Angela Litz, Omar El Ayoubi

|Nov 08, 2023
Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability.

Mirja Harms, Rikke Fabech Hansson, Andrea Gilg

Pageof 2

Frequent Collaborators

8 joint publications

Jan Münch

4 joint publications

Armando Rodríguez-Alfonso

3 joint publications

Ludger Ständker

2 joint publications

Rüdiger Groß